References
- Ahmed, M., Malik, M., Teselink, J., Lanctôt, K. L., & Herrmann, N. (2019). Current agents in development for treating behavioral and psychological symptoms associated with dementia. Drugs & Aging, 36(7), 589–605. https://doi.org/https://doi.org/10.1007/s40266-019-00668-7
- Barrow, P., & Clemann, N. (2021). Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2018 and 2019. Reproductive Toxicology (Elmsford, N.Y.), 99, 144–151. https://doi.org/https://doi.org/10.1016/j.reprotox.2020.06.013
- Calabrese, J. R., Durgam, S., Satlin, A., Vanover, K. E., Davis, R. E., Chen, R., Kozauer, S. G., Mates, S., & Sachs, G. S. (2021). Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: A phase 3 randomized placebo-controlled trial. The American Journal of Psychiatry. Advance online publication. https://doi.org/https://doi.org/10.1176/appi.ajp.2021.20091339
- Corponi, F., Fabbri, C., Bitter, I., Montgomery, S., Vieta, E., Kasper, S., Pallanti, S., & Serretti, A. (2019). Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 29(9), 971–985. https://doi.org/https://doi.org/10.1016/j.euroneuro.2019.06.008
- Correll, C. U., Davis, R. E., Weingart, M., Saillard, J., O’Gorman, C., Kane, J. M., Lieberman, J. A., Tamminga, C. A., Mates, S., & Vanover, K. E. (2020). Efficacy and safety of lumateperone for treatment of schizophrenia: A randomized clinical trial. JAMA Psychiatry, 77(4), 349–358. https://doi.org/https://doi.org/10.1001/jamapsychiatry.2019.4379
- Correll, C. U., Vanover, K. E., Davis, R. E., Chen, R., Satlin, A., & Mates, S. (2021). Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophrenia Research, 228, 198–205. https://doi.org/https://doi.org/10.1016/j.schres.2020.12.006
- Edinoff, A., Wu, N., deBoisblanc, C., Feltner, C. O., Norder, M., Tzoneva, V., Kaye, A. M., Cornett, E. M., Kaye, A. D., Viswanath, O., & Urits, I. (2020). Lumateperone for the treatment of schizophrenia. Psychopharmacology Bulletin, 50(4), 32–59.
- Frampton, J. E. (2020). Lumateperone in schizophrenia: A profile of its use. Drugs & Therapy Perspectives, 36(11), 477–484. https://doi.org/https://doi.org/10.1007/s40267-020-00780-4
- Greenwood, J., Acharya, R. B., Marcellus, V., & Rey, J. A. (2021). Lumateperone: A novel antipsychotic for schizophrenia. The Annals of Pharmacotherapy, 55(1), 98–104. https://doi.org/https://doi.org/10.1177/1060028020936597
- Intra-Cellular Therapies, Inc. (2021a, February 25). Intra-cellular therapies reports fourth quarter and full-year 2020 financial results and provides corporate update. GlobeNewswire. https://www.globenewswire.com/en/news-release/2021/02/25/2182351/30597/en/Intra-Cellular-Therapies-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-And-Provides-Corporate-Update.html
- Intra-Cellular Therapies, Inc. (2021b, August 9). Intra-cellular therapies reports second quarter 2021 financial results and provides corporate update. GlobeNewswire. https://www.globenewswire.com/en/news-release/2021/08/09/2277000/30597/en/Intra-Cellular-Therapies-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html
- Jankowska, A., Wesolowska, A., Pawlowski, M., & Chlon-Rzepa, G. (2018). Multi-target-directed ligands affecting serotonergic neurotransmission for Alzheimer’s disease therapy: Advances in chemical and biological research. Current Medicinal Chemistry, 25(17), 2045–2067. https://doi.org/https://doi.org/10.2174/0929867324666170529122802
- Kane, J. M., Durgam, S., Satlin, A., Vanover, K. E., Chen, R., Davis, R., & Mates, S. (2021). Safety and tolerability of lumateperone for the treatment of schizophrenia: A pooled analysis of late-phase placebo- and active-controlled clinical trials. International Clinical Psychopharmacology, 36(5), 244–250. https://doi.org/https://doi.org/10.1097/YIC.0000000000000371
- Kearns, B., Cooper, K., Cantrell, A., & Thomas, C. (2021). Schizophrenia treatment with second-generation antipsychotics: A multi-country comparison of the costs of cardiovascular and metabolic adverse events and weight gain. Neuropsychiatric Disease and Treatment, 17, 125–137. https://doi.org/https://doi.org/10.2147/NDT.S282856
- Liu, A. (2020, September 9). Intra-cellular’s caplyta could cruise toward blockbusterland with bipolar depression win: Analyst. Fierce Pharma. https://www.fiercepharma.com/marketing/intra-cellular-s-caplyta-could-cruise-toward-blockbuster-land-bipolar-depression-win
- Porsteinsson, A. P., & Antonsdottir, I. M. (2017). An update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opinion on Pharmacotherapy, 18(6), 611–620. https://doi.org/https://doi.org/10.1080/14656566.2017.1307340
- Snyder, G. L., Vanover, K. E., Davis, R. E., Li, P., Fienberg, A., & Mates, S. (2021). A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. Advances in Pharmacology (San Diego, Calif.), 90, 253–276. https://doi.org/https://doi.org/10.1016/bs.apha.2020.09.001
- Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O’Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., Nestler, E. J., Davis, R. E., Wennogle, L. P., & Mates, S. (2015). Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology, 232(3), 605–621. https://doi.org/https://doi.org/10.1007/s00213-014-3704-1
- Syed, A. B., & Brašić, J. R. (2021). The role of lumateperone in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology, 11, 20451253211034019. https://doi.org/https://doi.org/10.1177/20451253211034019
- Vanover, K. E., Davis, R. E., Zhou, Y., Ye, W., Brašić, J. R., Gapasin, L., Saillard, J., Weingart, M., Litman, R. E., Mates, S., & Wong, D. F. (2019). Dopamine D2 receptor occupancy of lumateperone (ITI-007): A positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 44(3), 598–605. https://doi.org/https://doi.org/10.1038/s41386-018-0251-1
- Vyas, P., Hwang, B. J., & Brašić, J. R. (2020). An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy, 21(2), 139–145. https://doi.org/https://doi.org/10.1080/14656566.2019.1695778
- Yuan, S., Yu, B., & Liu, H. M. (2020). New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry, 205, 112667. https://doi.org/https://doi.org/10.1016/j.ejmech.2020.112667